Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 9.64 crore in June 2025 down 42.65% from Rs. 16.81 crore in June 2024.
Story continues below Advertisement
Quarterly Net Loss at Rs. 52.03 crore in June 2025 up 46.27% from Rs. 96.84 crore in June 2024.
EBITDA stands negative at Rs. 43.31 crore in June 2025 up 53.71% from Rs. 93.56 crore in June 2024.
Sun Pharma Adv shares closed at 148.61 on August 01, 2025 (NSE) and has given -6.45% returns over the last 6 months and -31.52% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'25 | Mar'25 | Jun'24 | | Net Sales/Income from operations | 9.64 | 27.19 | 16.81 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 9.64 | 27.19 | 16.81 | | EXPENDITURE | | Consumption of Raw Materials | 5.13 | 5.70 | 4.53 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 27.68 | 24.83 | 28.94 | | Depreciation | 2.54 | 2.55 | 2.76 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 29.16 | 50.58 | 78.46 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -54.87 | -56.47 | -97.88 | | Other Income | 9.02 | -- | 1.56 | | P/L Before Int., Excpt. Items & Tax | -45.85 | -56.47 | -96.32 | | Interest | 6.18 | 4.51 | 0.52 | | P/L Before Exceptional Items & Tax | -52.03 | -60.98 | -96.84 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -52.03 | -60.98 | -96.84 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -52.03 | -60.98 | -96.84 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -52.03 | -60.98 | -96.84 | | Equity Share Capital | 32.45 | 32.45 | 32.45 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -1.60 | -1.88 | -2.98 | | Diluted EPS | -1.60 | -1.88 | -2.98 | | EPS After Extra Ordinary | | Basic EPS | -1.60 | -1.88 | -2.98 | | Diluted EPS | -1.60 | -1.88 | -2.98 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
